Evaluating Low-Dose Intra-Arterial Alteplase After Successful Endovascular Thrombectomy for Acute Ischemic Stroke Due to Large Vessel Occlusion
Led by 115 People's Hospital · Updated on 2026-09-25
416
Participants Needed
11
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating whether adding low-dose intra-arterial alteplase immediately after successful endovascular thrombectomy improves recovery in adults who have suffered an acute ischemic stroke caused by blockage in the large arteries of the brains anterior circulation. This phase 3, multicenter, randomized study compares functional outcomes between patients receiving adjunctive alteplase plus standard care and those receiving standard care alone after thrombectomy. The goal is to determine if this combined treatment enhances neurological recovery without increasing major bleeding or death risks.
Participants who have a confirmed large vessel occlusion stroke and achieve successful reperfusion eTICI 2b-3 within 24 hours of symptom onset will be randomly assigned to either receive intra-arterial alteplase plus best medical management or best medical management alone. The alteplase dose is 0.225 mgkg up to a maximum of 22.5 mg, given immediately after thrombectomy. Endovascular thrombectomy is performed using approved techniques and devices according to guidelines. The study follows a parallel design with two treatment groups.
During the trial, participants will be assessed for neurological function and safety outcomes including symptomatic intracranial hemorrhage and mortality. The main measure is excellent functional outcome at 90 days, defined by a modified Rankin Scale score of 0-1. Secondary assessments include quality of life, stroke severity scores, reperfusion grade, and cost-effectiveness up to 12 months. Follow-up visits and evaluations will track recovery and safety over this period.
CONDITIONS
Brief Title
INtra-arterial AltEplase folloWing successfuL reperfusIoN After mEchanical Thrombectomy
Research Team
T
Thang H Nguyen, Assoc. Prof.
T
Trung Q Nguyen, MsC
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
No significant disability before stroke (modified Rankin Scale 0-1)
Clinical diagnosis of acute ischemic stroke with anterior large vessel occlusion
Time from symptom onset to randomization within 24 hours, including wake-up or unwitnessed stroke
Baseline NIH Stroke Scale score between 6 and 25
Imaging score (ASPECTS) of 6 or higher on CT or MRI
For patients with perfusion imaging, ischemic core volume 70 mL or less, mismatch volume 15 mL or more, mismatch ratio 1.8 or more
Evidence of blockage in specified brain arteries confirmed by angiography
Successful reperfusion after endovascular thrombectomy with eTICI score 2b-3
Informed consent obtained from patient or acceptable surrogate
You will not qualify if you...
Modified Rankin Scale score 2 or higher before stroke onset
Expected life expectancy less than 12 months due to advanced illness
Acute head trauma
Severe high blood pressure not responding to treatment (systolic >185 mmHg or diastolic >110 mmHg)
Active or recent major bleeding within 30 days
Contraindications to thrombolytic therapy (except time to treatment)
Pregnant women at stroke onset
Recent intracranial surgery within 30 days
Known bleeding disorders or anticoagulation factor deficiencies
Coagulation disorder with INR over 1.7 or recent use of certain anticoagulants
Low platelet count (<50 G/L)
Very low or very high blood glucose levels
Severe kidney failure or dialysis treatment
Suspected infections or vascular conditions causing stroke
Allergies to contrast agents or heparin
Significant brain swelling or herniation signs
Multiple vascular territory strokes or occlusions
Intracranial hemorrhage seen on imaging
Brain tumors with mass effect
Need for antiplatelet or anticoagulant therapy within 24 hours after thrombectomy
Vascular dissection suspected
Procedure complications or delays beyond limits
Complete recovery after rapid recanalization
Participation in conflicting clinical trials
Any condition making study participation unsafe or unlikely to complete follow-up
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 24 hours from symptom onset to treatment and randomization
Participants receive endovascular thrombectomy followed by random assignment to either adjunct intra-arterial alteplase plus standard care or standard care alone.
Treatment occurs immediately after thrombectomy; follow-up visits for assessments
Follow-up
Duration - 90 days
Participants are monitored for recovery and safety outcomes including functional status, neurological assessments, and adverse events for up to 90 days post-treatment.
Regular follow-up visits for assessments at specified intervals
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Comparing Cyclic Plunger and Static Manual Aspiration Thrombectomy Techniques
for Acute Large Vessel Occlusion Stroke Using Raptor Aspiration Catheter
Using Methinks AI Software to Speed Up Transfer Decisions for Acute Stroke Patients Needing Thrombectomy
Global Trial Comparing Intra-arterial Thrombolysis with Tenecteplase or Alteplase Versus No Thrombolysis After Endovascular Thrombectomy for Acute Ischemic Stroke
Multicenter Registry Study of Endovascular Treatment for Acute Ischemic Stroke
Comparing General Anesthesia and Procedural Sedation for Mechanical Thrombectomy in Severe Ischemic Stroke Patients
Multiomics Biobank Study for Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion at Multiple Centers
Effect of Controlled Moderate Hypercapnia Versus Normocapnia on Brain Blood Flow During General Anesthesia for Mechanical Thrombectomy in Acute Ischemic Stroke
Testing Combined Cooling and Thrombectomy Treatment for Acute Ischemic Stroke with Large Vessel Blockage
Study of Early Endovascular Treatment for Acute Ischemic Stroke Caused by Isolated Internal Carotid Artery Occlusion
Comparing Endovascular Therapy and Best Medical Treatment for Mild Acute Ischemic Stroke Caused by Large Vessel Blockage
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Effect of Intra-arterial Alteplase vs Placebo Following Successful Thrombectomy on Functional Outcomes in Patients With Large Vessel Occlusion Acute Ischemic Stroke: The CHOICE Randomized Clinical Trial.
Intra-arterial alteplase for acute ischaemic stroke after mechanical thrombectomy (PEARL): rationale and design of a multicentre, prospective, open-label, blinded-endpoint, randomised controlled trial.